Takeda Oncology
Elvira Baviera is a seasoned professional in the pharmaceutical industry, currently serving as a Customer Excellence Business Partner in Oncology at Takeda Oncology since September 2017, where responsibilities include market data analysis, physician targeting, and stakeholder engagement. Prior to this role, Elvira held positions at Takeda Italia focusing on customer experience and market data management, and at Mylan as a Business Intelligence Manager. Elvira's experience also includes significant roles at Abbott in customer analytics and product management, covering market analysis and marketing strategy development, as well as a foundational role at Nielsen that supported marketing strategy planning for FMCG and pharmaceutical companies. Elvira holds an Economics Degree in Business Administration from Università degli studi Roma TRE and completed a program at SDA Bocconi.
This person is not in the org chart
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.